Fig. 8.1 Blinatumomab has anti-CD19 single-chain Fv (scFv) fragment at N-terminal and anti-CD3 scFv fragment at C-terminal. Each scFv is composed of V light chain and V heavy chain. Each…
Fig. 20.1 Various causes of LSC development In recent years, new techniques have begun to revolutionize the diagnosis, prognosis, and classification of leukemia. More recently, the introduction of high-speed analysis…
Aza C Supportive care Crossover No. of patients % No. of patients % No. of patients % No. evaluated 99 92 49 CR 7 7* 0 0 5 10…
Reference Regimen Patients (no.) Median age (years) ORR (%) CR (%) OS Kantarjian et al. [19] Clofarabine monotherapy 112 71 46 38 41 weeks Faderl et al. [26]a Clofarabine +…
Fig. 12.1 The molecular mechanism of action of ATO in APL. ATO binds to the B2 domain of the PML moiety of the PML-RARĪ± protein, inducing binding of UBC9 followed…
Author Year IO Dose No. of patients Response (%) Advani A 2010 Single 1.8 mg/m2 FL: 22 FL: 68 DLBCL:26 DLBCL: 15 Ogura M 2010 Single 1.8 mg/m2 FL: 10…
Related posts: Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia: Clinical Pharmacology and Therapeutic Results Clinical Use of Clofarabine for Adults and Children with Leukemia Nelarabine Rituximab and Alemtuzumab for Chronic Lymphocytic…
Fig. 6.1 Treatment strategy of B-CLL by the GCLLSG. Abbreviations: FCR fludarabine, cyclophosphamide, and rituximab, BR bendamustine and rituximab, R-idelalisib rituximab and idelalisib, SCT stem cell transplantation, G-CLB obinutuzumab and…
Fig. 7.1 Chest X-ray at presentation showing widening mediastinum Fig. 7.2 CT chest at presentation showing the disease starting at the left neck to the lower mediastinum with pleural and…
Fig. 1.1 Pre-chemotherapy PET/CT scan (axial slices) demonstrating the extent of disease in the right neck Fig. 1.2 Pre-chemotherapy PET/CT scan (coronal view) demonstrating the extent of disease Pathology The…
